Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

Practice Exam

CPC Practice Exam and Study Guide Package

Practice Exam

What makes a good CPC Practice Exam? Questions and Answers with Full Rationale

CPC Exam Review Video

Laureen shows you her proprietary “Bubbling and Highlighting Technique”

Download your Free copy of my "Medical Coding From Home Ebook" at the top right corner of this page

Practice Exam

2018 CPC Practice Exam Answer Key 150 Questions With Full Rationale (HCPCS, ICD-9-CM, ICD-10, CPT Codes) Click here for more sample CPC practice exam questions with Full Rationale Answers

Practice Exam

Click here for more sample CPC practice exam questions and answers with full rationale

Giant Cell Tumor Excision

My provider is excising a giant cell tumor from the finger/palm. He’s proposing CPT codes 26145, 26145-59 and 26075. I’m having a hard time with this one because I think the correct CPT code is either 26118 or 26160. I’m leaning more towards 26118 but I’m not 100% sure. Also, I’m not really seeing a synovectomy so I’m not sure if this is billable..and I believe the arthrotomy would be included in the excision code?

Thanks in advance.

The right middle finger was approached volarly with a Brunner incision. We went ahead and utilized the previous incision, which was oblique over the A1 pulley. This was extended proximally. We extended it distally across the MP joint, PIP joint, and then DIP joint. Incising the skin sharply, we elevated up radially and ulnarly full-thickness flaps. We identified the flexor tendon sheath, identified the radial and ulnar neurovascular bundles extending out to the middle finger. Exposing the flexor tendon sheath, there was clear recurrence of the giant cell tumor right at the site of the previous lesion. We then went ahead and fully developed the sheath distally. The tumor had recurred and basically tracked down the sheath and it popped up distal to the A2 pulley over the PIP joint and all the way out to the DIP joint past the A5 pulley. We created a window, excising the lesion at the A1 pulley level. We resected the remnants of the A1 pulley, which had obvious involvement of the giant cell tumor. There was a large component of giant cell tumor behind the superficialis tendon. There was actually tumor that appeared to be in the chiasm of the superficialis. Basically working between the pulley windows, we then went ahead and resected all the tumor that we could visualize out past A2. Just distal to A2, there was another lesion, kind of within the sheath itself. We pulled the superficialis and profundus out of the way and got the tumor there, and then working our way out distally, resected everything that we could while retaining the pulleys and the flexor tendons themselves. Once tumor had been excised all the way out to the DIP joint level, we, once again, inspected in and around the profundus and superficialis at every single level, making sure there were no remnants. Behind the A1 pulley over the volar aspect of the MP joint, it did appear that there was a lesion, which did extend through the volar capsule and possibly could have been the original lesion. We excised the small component of volar capsule and got into the MP joint volarly. There was no obvious lesion within the MP joint. The wounds were thoroughly irrigated. We then went ahead and closed the wounds using a 4-0 nylon in an interrupted fashion. We did place a small piece of Esmarch in proximally as a drain. A sterile dressing was applied.

Medical Billing and Coding Forum

HIPAA Q&A: BAAs, fax logs, and cell phone use

HIPAA Q&A

BAAs, fax logs, and cell phone use

by Mary D. Brandt, MBA, RHIA, CHE, CHPS

 

Q: Are we required to have a business associate agreement (BAA) with an overseas vendor? We may begin working with a billing company based in India. I don’t believe HIPAA would apply to an overseas company but I’m not clear on our responsibilities in this situation.

 

A: As a covered entity under HIPAA, your organization is required to have BAAs with all vendors who have access to your PHI to perform a service on your behalf. This includes companies outside the U.S., like the billing company in India.

 

Q: Are we required to keep a log of all faxes sent that contain PHI?

 

A: There is no requirement to log all fax transmissions of PHI, but your staff must take steps to protect the information transmitted. Appropriate steps include using a cover sheet with a confidentiality statement, using pre-programmed fax numbers for frequent recipients, carefully checking numbers manually entered before transmission, and placing fax machines in secure locations.

 

Q: I recently took a position with a home health agency. The agency does not provide staff with company-owned cell phones to use to communicate with patients. Staff must use their personal cell phones and frequently receive voicemails and text messages from patients. Nurses are provided with laptops and all staff have a company email address and are encouraged to inform patients that if they must contact them after hours they should do so via email except in cases of emergency. However, most patients prefer to attempt to call.

I believe having staff use their personal cell phones for work is an unnecessary risk and I would like to find a solution. Are we required to inform patients that our staff do not have company-owned cell phones and they should be careful what information they leave in a voicemail or text message? Would it be best to instead ask patients to call our main number with questions and their doctor’s office in emergencies?

 

A: Requiring staff to use their personal cell phones for patient communications is a concern. It is intrusive for staff members to receive calls from patients even when they are not on duty, and patients may communicate sensitive information on unsecured devices. A better solution, as you suggested, would be to ask patients to call the agency’s main number for questions and their doctor’s office in emergencies. Using the agency’s number would allow questions to be directed to the staff member currently assigned to the patient.

 

Q: We recently received a request for a patient’s records. The patient transferred to another provider several years ago and we subsequently transferred all the patient’s records to the new provider. Should I direct the request to the provider the patient transferred to? I’m unsure that we should be responsible for retrieving and releasing information for this patient since we transferred the patient’s entire record to the new provider.

 

A: If you sent a copy of the patient’s records to the new provider and still have the original records, it would be appropriate for you to respond to the request. If you transferred all records to the new provider and no longer have the patient’s information, refer the request to the new provider.

 

Editor’s note: Brandt is a healthcare consultant specializing in healthcare regulatory compliance and operations improvement. She is also an advisory board member for BOH. This information does not constitute legal advice. Consult legal counsel for answers to specific privacy and security questions. Opinions expressed are those of the author and do not represent HCPro or ACDIS. Email your HIPAA questions to Associate Editor Nicole Votta at [email protected].

HCPro.com – Briefings on HIPAA

Assistance with umbilical cord stem cell application for internal med/ortho etc

I was approached by a gentleman that previously had a collection company producing his claims. Here is the situation. He is NOT a provider, yet has an 2 NPI’s. One has the taxonomy of "blood work" yet is not considered a lab. He receives donated umbilical cord blood typically from a C-section. The blood/vein is removed and taken away to the lab where the blood is spun in a machine until only stem cells are left. These stem cells are applied/sprayed I internal or orthopedic cases where the first surgery was not successful. I am trying to find out the codes to bill the patients insurance as a "dme/product vendor" because the owner is not a physician and is not performing the surgery. The frozen stem cells are available for use as the physician deems necessary. The 40+ cases performed, the patients are doing remarkably well.

He had a prior billing company that coded the same codes and are :
38205
38207
38208
38212
38214
38215
38240
All were billed on 4 lines. The 1st line was standard CPT code then the following 3 utilized 59 modifier. He should be able to code for these services as the lab/machine prepared the umbilical cord blood into stem cell and was frozen, preserved, thawed etc. Unfortunately the previous billing company informed him he could utilize the same pre-cert/pre-auth as the hospital! I’m not sure how they stay in business.

Does anyone have any information on this fairly new procedure? Obviously it is allogeneic as it is a different donor aka maternal mother!

The other downfall is the "old school" MD did not state how many CC’s/units utilized however it should state 4 cc’s so that is why I am believing they billed a total of 4 units ??

If someone has experience and can lead me to it, I would GREATLY appreciate it.

Thank you

Medical Billing and Coding Forum